147 related articles for article (PubMed ID: 10739001)
1. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
3. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
4. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
6. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].
Csordás K; Eipel O; Hegyi M; Csóka M; Pap E; Kovács G
Orv Hetil; 2011 Oct; 152(40):1609-17. PubMed ID: 21945870
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
10. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
11. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
12. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
14. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia.
Wall AM; Gajjar A; Link A; Mahmoud H; Pui CH; Relling MV
Leukemia; 2000 Feb; 14(2):221-5. PubMed ID: 10673736
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate plasma pharmacokinetics: importance of assay method.
Eksborg S; Albertioni F; Rask C; Beck O; Palm C; Schroeder H; Peterson C
Cancer Lett; 1996 Nov; 108(2):163-9. PubMed ID: 8973590
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.
Aumente D; Buelga DS; Lukas JC; Gomez P; Torres A; García MJ
Clin Pharmacokinet; 2006; 45(12):1227-38. PubMed ID: 17112298
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]